Next Article in Journal
Probiotic Properties and Potentiality of Lactiplantibacillus plantarum Strains for the Biological Control of Chalkbrood Disease
Next Article in Special Issue
Raman Characterization of Fungal DHN and DOPA Melanin Biosynthesis Pathways
Previous Article in Journal
The Known Unknowns of the Immune Response to Coccidioides
Previous Article in Special Issue
Cryo-Electron Tomography of Candida glabrata Plasma Membrane Proteins
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 7
Issue 5
10.3390/jof7050378
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents

by
Ourania Georgacopoulos
1,*,
Natalie S. Nunnally
1,
Eric M. Ransom
2,
Derek Law
3,
Mike Birch
3,
Shawn R. Lockhart
1 and
Elizabeth L. Berkow
1
1
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
2
Association of Public Health Laboratories, Silver Springs, MD 20910, USA
3
F2G Ltd., Manchester M30 0LX, UK
*
Author to whom correspondence should be addressed.
J. Fungi 2021, 7(5), 378; https://0-doi-org.brum.beds.ac.uk/10.3390/jof7050378
Submission received: 7 April 2021 / Revised: 3 May 2021 / Accepted: 8 May 2021 / Published: 12 May 2021
(This article belongs to the Special Issue The Application of Structural Biology in Antifungal Drug Discovery)
Browse Figure
Versions Notes

Abstract

:
Olorofim is a novel antifungal drug that belongs to the orotomide drug class which inhibits fungal dihydroorotate dehydrogenase (DHODH), thus halting pyrimidine biosynthesis and ultimately DNA synthesis, cell growth and division. It is being developed at a time when many invasive fungal infections exhibit antifungal resistance or have limited treatment options. The goal of this study was to evaluate the in vitro effectiveness of olorofim against a large collection of recently isolated, clinically relevant American mold isolates. In vitro antifungal activity was determined for 246 azole-susceptible Aspergillus fumigatus isolates, five A. fumigatus with TR34/L98H-mediated resistance, 19 Rhizopus species isolates, 21 Fusarium species isolates, and one isolate each of six other species of molds. Olorofim minimum inhibitory concentrations (MICs) were compared to antifungal susceptibility testing profiles for amphotericin B, anidulafungin, caspofungin, isavuconazole, itraconazole, micafungin, posaconazole, and voriconazole. Olorofim MICs were significantly lower than those of the echinocandin and azole drug classes and amphotericin B. A. fumigatus wild type and resistant isolates shared the same MIC50 = 0.008 μg/mL. In non-Aspergillus susceptible isolates (MIC ≤ 2 μg/mL), the geometric mean (GM) MIC to olorofim was 0.54 μg/mL with a range of 0.015–2 μg/mL. Olorofim had no antifungal activity (MIC ≥ 2 μg/mL) against 10% of the collection (31 in 297), including some isolates from Rhizopus spp. and Fusarium spp. Olorofim showed promising activity against A. fumigatus and other molds regardless of acquired azole resistance.

1. Introduction

Invasive fungal infections (IFI) are increasing in prevalence globally in parallel with the increase in antifungal drug resistance, posing a serious challenge for healthcare providers [1,2,3]. Advances in immunosuppressive therapies have resulted in a growing population of immunocompromised patients who are vulnerable to fungal infections including individuals with HIV, cancer patients, organ transplant recipients, stem cell transplant recipients, and people with long-term hospitalizations [4]. Several pathogenic mold species have exhibited increasing antifungal resistance, chief among them Aspergillus fumigatus [5]. Invasive aspergillosis is the predominant invasive mold infection in patients, with Aspergillus increasingly resistant to first line triazole antifungals [6,7]. Other opportunistic molds, such as Rhizopus, Fusarium, and some dematiaceous mold species, also contribute to the burden of IFI in the healthcare setting and are increasingly refractory to available antifungal therapies [8].
Azoles, echinocandins, and the polyene amphotericin B are the only antifungals currently approved to treat invasive mold infections (IMIs). Although amphotericin B is often an effective therapy, it is associated with many adverse side effects including infusion-related reactions and nephrotoxicity [9]. Azole use can have side effects as well. Azoles are not 100% selective for binding to fungal targets (they can also bind to human CYP450) which can cause drug-drug interactions [10]. Long-term azole use can lead to acquired drug resistance, which is a concern as it leads to higher rates of treatment failure and longer hospital stays [11]. In addition to increasing azole resistance due to broader use of azoles in medicine, the use of azole compounds as agricultural fungicides has led to an increase in azole-resistant A. fumigatus, especially in Europe [11,12,13,14,15]. Challenges also exist in treating other rare or unusual mold infections. The paucity of new drug development in the antifungal pipeline has limited the treatment options for rare and difficult to treat molds such as the Mucorales, Fusarium and dematiaceous molds [16,17]. New drug development is needed to help combat these infections.
Olorofim (F2G Limited, Manchester, UK) is the first antifungal in a new drug class known as orotomides. Olorofim inhibits fungal dihydroorotate dehydrogenase (DHODH), halting pyrimidine biosynthesis and ultimately impacting DNA synthesis, cell growth and division. DHODH is a unique drug target rendering it less likely to be impacted by other acquired resistance mechanisms [18]. The fungal DHODH target differs significantly from human DHODH, minimizing target-based drug toxicity [19].
Olorofim displays antifungal activity against numerous species of molds including Penicillium spp., Coccidioides spp., Histoplasma capsulatum, Blastomyces dermatitidis, Fusarium spp., Scedosporium spp., Lomentospora prolificans, Scopulariopsis brevicaulis, and Aspergillus spp. [18,19,20,21,22,23,24,25,26,27,28]. The FDA has granted olorofim breakthrough therapy designation and orphan drug designation for treatment of invasive aspergillosis as well as for infections due to Lomentospora/Scedosporium, Scopulariopsis, and central nervous system (CNS) coccidioidomycosis. An open-label single-arm phase 2b study for treatment of invasive fungal infections in patients who lack treatment options is underway (ClinicalTrials.gov Identifier: NCT03583164) [29].
In this study we assessed the in vitro efficacy of olorofim compared to MIC values of traditional antifungals using the Clinical and Laboratory Standards Institute (CLSI) reference method for antifungal susceptibility testing. Olorofim, azoles, echinocandins, and polyenes were tested against 297 contemporary mold isolates, including those which are refractory to currently available antifungal treatments.

2. Materials and Methods

A total of 297 mold isolates were tested, including azole-susceptible A. fumigatus (n = 246), azole-resistant A. fumigatus with the TR34/L98H (n = 3) and TR34/L98H/S297T/F495I (n = 2) mutations, Rhizopus microsporus (n = 3), Rhizopus oryzae (n = 16), Fusarium chlamydosporum (n = 1), Fusarium dimerum (n = 2), Fusarium moniliforme (n = 1), Fusarium oxysporum (n = 5), Fusarium verticillioides (n = 1), Fusarium solani species complex (n = 11), and rare and unusual mold species including Phialemonium curvatum (n = 1), Phaeoacremonium parasticum (n = 1), Sarocladium kiliense (n = 1), Ramularia species (n = 1), Metarrhizium anisopliae (n = 1), and Pleurostomophora richardsiae (n = 1). All mold isolates were received at CDC between 1998 and 2019 as part of ongoing surveillance and routine diagnostic testing and come from both clinical and environmental sources. All isolates were clinical except for 12 R. microsporus and R. oryzae isolates which came from environmental sources, and 90% of isolates were received between 2017 and 2019.
A. fumigatus isolates were screened for itraconazole, posaconazole, and voriconazole resistance using a plate assay as described [30]. Isolates with breakthrough growth on the plate were confirmed as resistant to azoles by standard broth microdilution according to the Clinical and Laboratory Standards Institute (CLSI) document M-38 [31]. Epidemiologic cutoff values for A. fumigatus of ≥2 μg/mL for itraconazole and/or ≥1 μg/mL for voriconazole were used to indicate reduced antifungal activity. Mutations in the Cyp51A gene were confirmed through gene sequencing as previously described [32].
Susceptibility testing of mold isolates against olorofim followed the methods described in CLSI reference standard M38-A2 (M38 Reference). F901318 (olorofim) powder was donated by F2G Limited (Manchester, UK). Dilutions of olorofim were prepared using DMSO and the concentration range set to (0.0001–2 μg/mL) in 2-fold serial dilutions. Olorofim drug plates were prepared using 96-well polystyrene round-bottom microwell plates (Thermo Scientific, Item ID# 262162) and 100 μL of synthetic medium RPMI-1640 was added to the plates before dispensing the antifungal. The HP D300e Digital Dispenser, HP Dispensing Software and HP T8+ and HP D4+ Dispensing cassettes were used to dispense the predetermined dosages of olorofim [33]. Drug plates were prepared ahead of time and stored at −80 °C until day of use, when they were removed from the freezer and allowed to thaw in a 37 °C incubator.
Isolates were cultured onto Sabouraud Dextrose (SabDex) agar slants and incubated for 2–7 days at 35 °C. The suspension was prepared by adding 1 mL of Tween 20 (2%, prepared in molecular grade H2O) to each agar slant. The solution was drawn off and heavier particles allowed to settle. Absorbance was determined by measuring the optical density at 530 nm (OD530) using a spectrophotometer and adjusted to the desired range with sterile water as follows: OD530 of 0.09 to 0.13 for Aspergillus and dematiaceous spp., and OD530 of 0.15–0.17 for Fusarium and Rhizopus spp. For antifungal susceptibility testing the adjusted suspension was diluted 1:50 in RPMI-1640 broth and 0.1 mL of the diluted inoculum added to each well. A growth control well containing no antifungal agent was included, in addition to a well containing only the medium and nuclease free water as a negative control. Quality control isolates for each species tested are listed in Table 1.
Olorofim antifungal activity was compared with results for other drugs from antifungal susceptibility testing using custom frozen panels from TREK Diagnostics (Thermo Fisher Scientific, Oakwood Village, OH, USA), which included anidulafungin, caspofungin, isavuconazole, itraconazole, micafungin, posaconazole, and voriconazole. Amphotericin B susceptibility was determined using Etest (bioMérieux, France). MICs were read for amphotericin B and the azoles, whereas the MEC was read for the echinocandins as specified in the CLSI’s M38 [31]. Endpoints were recorded at 24 h for Rhizopus spp. and 48 h for A. fumigatus, Fusarium spp., Phialemonium curvatum, Phaeoacremonium parasticum, Sarocladium kiliense, Ramularia species, Metarrhizium anisopliae, and Pleurostomophora richardsiae.

3. Results

3.1. CLSI Reference Method MIC Results for Olorofim, Azoles, Echinocandins and Amphotericin B against Molds

3.1.1. Olorofim

Olorofim MIC results for each species tested are listed in Table 2. Olorofim showed consistent antifungal activity when tested against azole-susceptible A. fumigatus isolates (MIC50 = 0.008 μg/mL). All A. fumigatus isolates fell within a one to two dilution range of the MIC50 (0.008 μg/mL) (Figure 1). The five azole-resistant A. fumigatus isolates with Cyp51A-associated point mutations had MIC values of 0.008 μg/mL, the same as the MIC50 of azole-susceptible A. fumigatus isolates.
Olorofim showed variable antifungal activity amongst Fusarium spp. isolates. Olorofim showed no antifungal activity against F. chlamydosporum in the range tested (MIC > 2 μg/mL). F. dimerum and F. solani species complex MICs were in the upper range of tested concentrations or showed no antifungal effect (MIC range 2 to >2 μg/mL). Olorofim had a wide range of antifungal activity against F. oxysporum (MIC = 0.12 to >2 μg/mL). F. moniliforme and F. verticilloides had low olorofim MICs compared to other Fusarium spp. tested (MIC = 0.03 and 0.50 μg/mL, respectively). Phialemonium curvatum and Phaeoacremonium parasiticum were in the upper range tested (MIC = 2 μg/mL), while Sarocladium kiliense (MIC = 0.5 μg/mL), Ramularia spp. (MIC = 0.015 μg/mL), Metarrhizium anisopliae (MIC = 0.5 μg/mL), and Pleurostomophora richardsiae (MIC = 0.06 μg/mL) all had low olorofim MIC values. Olorofim did not show in vitro inhibitory activity against Rhizopus microsporus or Rhizopus oryzae in the range tested, in agreement with other studies that show olorofim is ineffective against members of the Mucorales group.

3.1.2. Azoles

The collection was tested against the following azoles: isavuconazole, itraconazole, posaconazole, and voriconazole. Aside from A. fumigatus, voriconazole showed little antifungal activity against most isolates in this collection although the MICs to R. microsporus and A. fumigatus with mutations in TR34/L98H and TR34/L98H/S297T/F495I were variable. For itraconazole, isolates of R. oryzae had variable MICs (range 0.03 μg/mL to >16 μg/mL) while all other species had only high MICs. R. microsporus, F. verticillioides, and Ramularia species all had low MICs to isavuconazole (≤1 μg/mL), however isavuconazole was not as effective against the remaining species, all of which had MIC in the upper range (≥8 μg/mL). Consistent with the results for itraconazole, R. oryzae had variable MICs to isavuconazole (range 0.25 μg/mL to >8 μg/mL). For posaconazole, R. microsporus, F. verticilloides, P. curvatum, P. parasiticum, and Ramularia species all had low MICs (≤0.5 μg/mL). All other species had high MICs to posaconazole (≥2 μg/mL) except for R. oryzae, which had variable MICs (range 0.03 μg/mL to >16 μg/mL).

3.1.3. Echinocandins

The collection was tested against anidulafungin, caspofungin, and micafungin. Minimal effective concentrations (MECs) were high for all three echinocandins, ≥2 μg/mL for R. oryzae, F. chlamydosporum, F. dimerum, F. verticilloides, P. curvatum, and P. parasiticum. For S. kiliense, R. microsporus, F. oxysporum, and Fusarium solani species complex echinocandin MECs were variable (range 0.06 μg/mL to >16 μg/mL). The remainder of the collection displayed low MECs to the echinocandins (≤0.125 μg/mL).

3.1.4. Amphotericin B

Amphotericin B was more effective than either the azoles or echinocandins. Rhizopus microsporus, F. moniliforme, P. curvatum, P. parasiticum, and P. richardsiae all exhibited low MICs to amphotericin B (≤0.5 μg/mL). Fusarium chlamydosporum, F. dimerum, F. verticilloides, S. kiliense, Ramularia species, and Metarrhizium anisopliae all exhibited high MICs to amphotericin B (≥2 μg/mL). The MIC values for R. oryzae, F. oxysporum, and F. solani species complex were variable (range 0.25 μg/mL to >32 μg/mL).

4. Discussion

Our study corroborates previous findings showing the in vitro efficacy of olorofim against A. fumigatus and provides new data on rare and unusual molds. Previous studies exploring efficacy of olorofim against Aspergillus spp. found similar MIC ranges and susceptibility patterns. In Jørgensen et al., 235 A. fumigatus isolates were tested using the EUCAST method, resulting in a geometric mean MIC of 0.037 μg/mL, which is consistent with our results despite the differences in testing methodology [20,34]. Buil et al. tested 10 A. fumigatus WT isolates and reported an olorofim MIC50 of 0.06 μg/mL, the olorofim MICs of isolates with the TR34/L98H mutation were in the same range as the WT isolates (0.031–0.125 mg/L) [18]. As olorofim has a completely different target to the azoles, cross-resistance would not be expected. Consistent with this, an in-silico model predicts olorofim to possess a low probability of developing resistance in A. fumigatus [35]. A limitation of this study is the small sample size (n = 5) of A. fumigatus isolates with the TR34/L98H mutation that were tested. The addition of our large collection of contemporary A. fumigatus isolates contributes to our knowledge of the wild type MIC range of this species against olorofim and will help with the establishment of epidemiological cutoff values. In addition, it shows that US isolates of A. fumigatus have similar susceptibility to olorofim as European isolates.
Jørgensen et al. used the EUCAST method to test olorofim susceptibility against different species of Fusarium and found F. dimerum and F. solani to have MICs > 1μg/mL [20]. Our study tested multiple species of Fusarium and found elevated MICs of ≥ 2 μg/mL for all species except F. verticillioides (MIC 0.50 μg/mL) and an isolate of F. oxysporum. Wiederhold et al. similarly found F. verticillioides had low MIC values with a range of 0.03–0.125 μg/mL, indicating olorofim is likely to be active against F. verticillioides, but in many cases Fusarium are not identified to species so this observation may not be clinically relevant [36]. It was also shown that olorofim activity against Fusarium is endpoint dependent, and that using a 50% inhibition endpoint results in lower MICs [36].
Rhizopus species remain difficult to treat and can have very high MIC values to amphotericin B and posaconazole [17,37,38,39]. Isavuconazole is the only antifungal with a US Food and Drug Administration indication for use against Mucorales. A recent study looked at R. microsporus susceptibility to olorofim and found no antifungal activity (n = 4, MIC ≥ 1) [20]. The lack of antifungal activity of olorofim against Mucorales species can be explained by differences in the DHODH drug target. Mucorales’ DHODH is distantly related to the DHODH of susceptible fungal species [19]. Dematiaceous and other rare molds can cause serious infections and are difficult to treat as many antifungals have little activity and effective treatment information is lacking. We included several rare molds from clinical cases of fungal infection to highlight the possible range of olorofim activity beyond the most commonly seen fungal infections. The activity of olorofim cannot be generalized for these rare infections but has shown good activity for some species and warrants further investigation. In conclusion we have confirmed the efficacy of olorofim against both WT and azole-resistant A. fumigatus seen in other studies as well demonstrated in vitro efficacy of olorofim against several Fusarium spp. and rare molds.

Author Contributions

Conceptualization, E.L.B., O.G., N.S.N., E.M.R., M.B. and D.L.; Methodology, E.L.B., O.G., N.S.N. and E.M.R.; Software, N.S.N.; Validation, N.S.N.; Formal Analysis, O.G. and S.R.L.; Investigation, O.G.; Data Curation, E.M.R.; Writing—Original Draft Preparation, O.G. and N.S.N.; Writing—Review & Editing, O.G., S.R.L., E.L.B., E.M.R., M.B. and D.L.; Supervision, S.R.L. and E.L.B.; Project Administration, E.L.B. and S.R.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The isolates used in this study were approved for use by the Institutional Review Board of the Centers for Disease Control and Prevention.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We are grateful to the members of the Mycotic Diseases Branch (MDB) at the Centers for Disease Control and Prevention (CDC) for their support.

Conflicts of Interest

M.B. and D.L. are employees and shareholders of F2G Ltd.

Disclaimer

The findings and the conclusions in this report are those of the authors and do not necessarily represent the view of the Centers for Disease Control and Prevention. Use of trade names if for identification only and does not imply endorsement.

References

  1. Pfaller, M.A.; Pappas, P.G.; Wingard, J.R. Invasive Fungal Pathogens: Current Epidemiological Trends. Clin. Infect. Dis. 2006, 43, S3–S14. [Google Scholar] [CrossRef]
  2. Rauseo, A.M.; Coler-Reilly, A.; Larson, L.; Spec, A. Hope on the Horizon: Novel Fungal Treatments in Development. Open Forum Infect Dis. 2020, 7, ofaa016. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Vallabhaneni, S.; Mody, R.K.; Walker, T.; Chiller, T. The Global Burden of Fungal Diseases. Infect Dis. Clin. N. Am. 2016, 30, 1–11. [Google Scholar] [CrossRef]
  4. Brown, G.D.; Denning, D.W.; Gow, N.A.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012, 4, 165rv13. [Google Scholar] [CrossRef] [Green Version]
  5. Kosmidis, C.; Denning, D.W. The clinical spectrum of pulmonary aspergillosis. Thorax 2015, 70, 270–277. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Verweij, P.E.; Mellado, E.; Melchers, W.J. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 2007, 356, 1481–1483. [Google Scholar] [CrossRef] [Green Version]
  7. Lestrade, P.P.A.; Meis, J.F.; Melchers, W.J.G.; Verweij, P.E. Triazole resistance in Aspergillus fumigatus: Recent insights and challenges for patient management. Clin. Microbiol. Infect. 2019, 25, 799–806. [Google Scholar] [CrossRef] [PubMed]
  8. Enoch, D.A.; Yang, H.; Aliyu, S.H.; Micallef, C. The Changing Epidemiology of Invasive Fungal Infections. Methods Mol. Biol. 2017, 1508, 17–65. [Google Scholar] [PubMed]
  9. Safdar, A.; Ma, J.; Saliba, F.; Dupont, B.; Wingard, J.R.; Hachem, R.Y.; Mattiuzzi, G.N.; Chandrasekar, P.H.; Kontoyiannis, D.P.; Rolston, K.V.; et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: A review and meta-analysis. Medicine (Baltimore) 2010, 89, 236–244. [Google Scholar] [CrossRef]
  10. Townsend, R.; Dietz, A.; Hale, C.; Akhtar, S.; Kowalski, D.; Lademacher, C.; Lasseter, K.; Pearlman, H.; Rammelsberg, D.; Schmitt-Hoffman, A.; et al. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole with Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults. Clin. Pharmacol. Drug. Dev. 2017, 6, 44–53. [Google Scholar] [CrossRef] [Green Version]
  11. Verweij, P.E.; Chowdhary, A.; Melchers, W.J.; Meis, J.F. Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles? Clin. Infect. Dis. 2016, 62, 362–368. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Perlin, D.S.; Rautemaa-Richardson, R.; Alastruey-Izquierdo, A. The global problem of antifungal resistance: Prevalence, mechanisms, and management. Lancet Infect. Dis. 2017, 17, e383–e392. [Google Scholar] [CrossRef]
  13. Chowdhary, A.; Kathuria, S.; Xu, J.; Meis, J.F. Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013, 9, e1003633. [Google Scholar] [CrossRef]
  14. Resendiz Sharpe, A.; Lagrou, K.; Meis, J.F.; Chowdhary, A.; Lockhart, S.R.; Verweij, P.E. Triazole resistance surveillance in Aspergillus fumigatus. Med. Mycol. 2018, 56 (Suppl. S1), 83–92. [Google Scholar] [CrossRef] [Green Version]
  15. Hurst, S.F.; Berkow, E.L.; Stevenson, K.L.; Litvintseva, A.P.; Lockhart, S.R. Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA. J. Antimicrob. Chemother. 2017, 72, 2443–2446. [Google Scholar] [CrossRef]
  16. Wiederhold, N.P. Antifungal resistance: Current trends and future strategies to combat. Infect. Drug Resist. 2017, 10, 249–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Dannaoui, E. Antifungal resistance in mucorales. Int. J. Antimicrob. Agents 2017, 50, 617–621. [Google Scholar] [CrossRef] [PubMed]
  18. Buil, J.B.; Rijs, A.J.M.M.; Meis, J.F.; Birch, M.; Law, D.; Melchers, W.J.G.; Verweij, P.E. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates. J. Antimicrob. Chemother. 2017, 72, 2548–2552. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Oliver, J.D.; Sibley, G.E.M.; Beckmann, N.; Dobb, K.S.; Slater, M.J.; McEntee, L.; du Pré, S.; Livermore, J.; Bromley, M.J.; Wiederhold, N.P.; et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc. Natl. Acad. Sci. USA 2016, 113, 12809–12814. [Google Scholar] [CrossRef] [Green Version]
  20. Jørgensen, K.M.; Astvad, K.M.T.; Hare, R.K.; Arendrup, M.C. EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs. Antimicrob. Agents Chemother. 2018, 62, e00487-18. [Google Scholar] [CrossRef] [Green Version]
  21. Wiederhold, N.P.; Najvar, L.K.; Jaramillo, R.; Olivo, M.; Birch, M.; Law, D.; Rex, J.H.; Catano, G.; Patterson, T.F. The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis. Antimicrob. Agents Chemother. 2018, 62, e00999-18. [Google Scholar] [CrossRef] [Green Version]
  22. du Pré, S.; Beckmann, N.; Almeida, M.C.; Sibley, G.E.M.; Law, D.; Brand, A.C.; Birch, M.; Read, N.D.; Oliver, J.D. Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob. Agents Chemother. 2018, 62, e00231-18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Rivero-Menendez, O.; Cuenca-Estrella, M.; Alastruey-Izquierdo, A. In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J. Antimicrob. Chemother. 2019, 74, 1586–1590. [Google Scholar] [CrossRef] [Green Version]
  24. Seyedmousavi, S.; Chang, Y.C.; Law, D.; Birch, M.; Rex, J.H.; Kwon-Chung, K.J. Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease. Antimicrob. Agents Chemother. 2019, 63, e00129-19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Lim, W.; Eadie, K.; Konings, M.; Rijnders, B.; Fahal, A.H.; Oliver, J.D.; Birch, M.; Verbon, A.; van de Sande, W. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim. J. Antimicrob. Chemother. 2020, 75, 936–941. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Biswas, C.; Law, D.; Birch, M.; Halliday, C.; Sorrell, T.C.; Rex, J.; Slavin, M.; Chen, S.C. In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Med. Mycol. 2018, 56, 1050–1054. [Google Scholar] [CrossRef]
  27. Talbot, J.J.; Frisvad, J.C.; Meis, J.F.; Hagen, F.; Verweij, P.E.; Hibbs, D.E.; Lai, F.; Groundwater, P.W.; Samson, R.A.; Kidd, S.E.; et al. cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex. Antimicrob. Agents Chemother. 2019, 63, e00632-19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Lackner, M.; Birch, M.; Naschberger, V.; Grässle, D.; Beckmann, N.; Warn, P.; Gould, J.; Law, D.; Lass-Flörl, C.; Binder, U. Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei. J. Antimicrob. Chemother. 2018, 73, 3068–3073. [Google Scholar] [CrossRef]
  29. Kennedy, T.; Graham, A.; Steiner, J. An open-label study in healthy volunteers to evaluate the potential for cytochrome P450 3A4 inhibition by F901318 using oral midazolam as a probe. In Proceedings of the ECCMID, Vienna, Austria, 22–25 April 2017. [Google Scholar]
  30. Guinea, J.; Verweij, P.E.; Meletiadis, J.; Mouton, J.W.; Barchiesi, F.; Arendrup, M.C. How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates. Clin. Microbiol. Infect. 2019, 25, 681–687. [Google Scholar] [CrossRef] [PubMed]
  31. Institute CaLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, M38, 3rd ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017. [Google Scholar]
  32. Berkow, E.L.; Nunnally, N.S.; Bandea, A.; Kuykendall, R.; Beer, K.; Lockhart, S.R. Detection of TR34/L98H CYP51A Mutation through Passive Surveillance for Azole-Resistant Aspergillus fumigatus in the United States from 2015 to 2017. Antimicrob. Agents Chemother. 2018, 62, e02240-17. [Google Scholar] [CrossRef] [Green Version]
  33. Smith, K.P.; Kirby, J.E. Verification of an Automated, Digital Dispensing Platform for At-Will Broth Microdilution-Based Antimicrobial Susceptibility Testing. J. Clin. Microbiol. 2016, 54, 2288–2293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Arendrup, M.C.; Meletiadis, J.; Mouton, J.W.; Guinea, J.; Cuenca-Estrella, M.; Lagrou, K.; Howard, S.J. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin. Microbiol. Infect. 2016, 22, 571. [Google Scholar] [PubMed] [Green Version]
  35. Buil, J.B.; Oliver, J.; Law, D.; Tehupeiory-Kooreman, M.; Rex, J.H.; Hokken, M.W.J.; Melchers, W.J.G.; Birch, M.; Verweij, P.E. Molecular Mechanism and frequency of olorofim resistance in Aspergillus fumigatus. In Proceedings of the Trends in Medical Mycology bi-annual meeting of the European Confederation of Medical Mycology (ECMM), Nice, France, 11–14 October 2019. [Google Scholar]
  36. Wiederhold, N.P.; Patterson, H.P.; Birch, M.; Law, D.; Rex, J. Evaluation of the In Vitro Activity of Olorofim against Fusarium Species. In Proceedings of the Trends in Medical Mycology bi-annual meeting of the European Confederation of Medical Mycology (ECMM), Nice, France, 11–14 October 2019. [Google Scholar]
  37. Vehreschild, J.J.; Birtel, A.; Vehreschild, M.J.; Liss, B.; Farowski, F.; Kochanek, M.; Sieniawski, M.; Steinbach, A.; Wahlers, K.; Fätkenheuer, G.; et al. Mucormycosis treated with posaconazole: Review of 96 case reports. Crit. Rev. Microbiol. 2013, 39, 310–324. [Google Scholar] [CrossRef]
  38. Marty, F.M.; Ostrosky-Zeichner, L.; Cornely, O.A.; Mullane, K.M.; Perfect, J.R.; Thompson, G.R., 3rd; Alangaden, G.J.; Brown, J.M.; Fredricks, D.N.; Heinz, W.J.; et al. VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect. Dis. 2016, 16, 828–837. [Google Scholar] [CrossRef]
  39. Skiada, A.; Lass-Floerl, C.; Klimko, N.; Ibrahim, A.; Roilides, E.; Petrikkos, G. Challenges in the diagnosis and treatment of mucormycosis. Med. Mycol. 2018, 56 (Suppl. S1), 93–101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Jof 07 00378 g001 550
Figure 1. Distribution of olorofim MICs for Aspergillus fumigatus isolates. † MIC 50; ‡ MIC 90.
Figure 1. Distribution of olorofim MICs for Aspergillus fumigatus isolates. † MIC 50; ‡ MIC 90.
Jof 07 00378 g001
Table
Table 1. Quality control isolates used for each fungal organism tested.
Table 1. Quality control isolates used for each fungal organism tested.
Quality Control or Reference StrainSpecies Tested
Aspergillus fumigatus ATCC MYA-3626Fusarium spp., Phialemonium curvatum, Phaeoacremonium parasiticum, Sarocladium kiliense, Ramularia sp., Metarrhizium anisopliae and Pleurostomophora richardsiae
Candida krusei ATCC 6258Rhizopus spp.
Azole susceptible A. fumigatus B7698
Azole resistant A. fumigatus B7815
(CDC internal controls)		A. fumigatus
Table
Table 2. MIC results of Olorofim and AFST testing using the CLSI M38-A2 Reference Method for Broth Dilution. MIC 50 and ranges listed in μg/mL. MIC is reported for species with only 1 isolate tested.
Table 2. MIC results of Olorofim and AFST testing using the CLSI M38-A2 Reference Method for Broth Dilution. MIC 50 and ranges listed in μg/mL. MIC is reported for species with only 1 isolate tested.
SpeciesOlorofimVoriconazoleAnidulafunginCaspofunginItraconazoleIsavuconazolePosaconazoleMicafunginAmphotericin B
A. fumigatus WT (n = 246)
MIC 500.008
Range0.004–0.03
A. fumigatus TR34/L98H (n = 5)
MIC 500.0082 16
Range0.008–0.0080.3–2 4–>16
R. microsporus (n = 3)
MIC 50>244160.060.50.5>80.06
Range2–>20.5–40.25–>160.25–>160.06–0.1250.125–10.06–0.1250.25–>80.016–0.125
R. oryzae (n = 16)
MIC 50>24>16>160.12540.3>81.5
Range>2–>21–88–>1616–>160.03–>160.25–>80.03–>164–>80.3–4
F. chlamydosporum (n = 1)
MIC 50>22>16>16>16>8>16>82
Range
F. dimerum (n = 2)
MIC 50>24>16>16>16>8>16>84
Range2–>24–48–>1616–>16>16–>168–>8>16–>162–>83–4
F. moniliforme (n = 1)
MIC 500.0320.060.125>16>8>160.020.5
Range
F. oxysporum (n = 5)
MIC 502161616>16>8>16824
Range0.12–>24–>160.125–>160.125–>16>16–>168–>82–>160.06–>80.8–>32
F. solani (n = 11)
MIC 50>2888>16>8>164>32
Range2–>21–>161–>162–>16>16–>16>8–>8>16–>160.125–>81.5–>32
F. verticilloides (n = 1)
MIC 500.51>16>160.310.06>8>32
Range
M. anisopliae (n = 1)
MIC 500.510.1250.06>168>16<0.008>32
Range
P. parasiticum (n = 1)
MIC 50218>16>1680.5>80.3
Range
P. curvatum (n = 1)
MIC 50218>160.580.125>80.125
Range
P. richardsiae (n = 1)
MIC 500.06 0.4
Range
Ramularia species (n = 1)
MIC 500.0151<0.008<0.0080.510.3<0.00816
Range
S. kiliense (n = 1)
MIC 500.5280.5>16>8>16412
Range
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Georgacopoulos, O.; Nunnally, N.S.; Ransom, E.M.; Law, D.; Birch, M.; Lockhart, S.R.; Berkow, E.L. In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents. J. Fungi 2021, 7, 378. https://0-doi-org.brum.beds.ac.uk/10.3390/jof7050378

AMA Style

Georgacopoulos O, Nunnally NS, Ransom EM, Law D, Birch M, Lockhart SR, Berkow EL. In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents. Journal of Fungi. 2021; 7(5):378. https://0-doi-org.brum.beds.ac.uk/10.3390/jof7050378

Chicago/Turabian Style

Georgacopoulos, Ourania, Natalie S. Nunnally, Eric M. Ransom, Derek Law, Mike Birch, Shawn R. Lockhart, and Elizabeth L. Berkow. 2021. "In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents" Journal of Fungi 7, no. 5: 378. https://0-doi-org.brum.beds.ac.uk/10.3390/jof7050378

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop